Home > Boards > Free Zone > Health and Sciences > Biotech Values

Preliminary files still available - since locally stored

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
read_this_n0w Member Profile
Followed By 238
Posts 14,288
Boards Moderated 3
Alias Born 07/07/06
160x600 placeholder
Top Company News of the Day
Cash-strapped China Evergrande New Energy Vehicle Group Ltd. has shelved plans to list on the Shanghai Stock Exchange, as the debt crisis at its parent, China Evergrande Group, weighs on market confidence.
Prudential to Raise US$2.4 Billion From Hong Kong Offer
Belgium Business Confidence Falls in September
Wheat Climbs on Indications of Tighter Supply -- Daily Grain Highlights
Front Month Nymex Natural Gas Rose 0.69% This Week to Settle at $5.1400 -- Data Talk
Front Month Nymex RBOB Gasoline Rose 0.75% This Week to Settle at $2.1875 -- Data Talk
Costco On Pace for Record High Close -- Data Talk
United Airlines Fined $1.9 Million for Violating Transportation Department's Tarmac-Delay Rule
California Attorney General Appeals Purdue Pharma's Sackler Settlement
2Q GDP Still Seen +6.6% -- Data Week Ahead
Italy to Launch Three New Government Bonds in 4Q
DAX Ends the Week 0.27% Higher at 15531.75 -- Data Talk
CAC 40 Index Ends the Week 1.04% Higher at 6638.46 -- Data Talk
STOXX Europe 50 Index Ends the Week 0.82% Higher at 3550.35 -- Data Talk
EURO STOXX 50 Index Ends the Week 0.67% Higher at 4158.51 -- Data Talk
STOXX Europe 600 Index Ends the Week 0.31% Higher at 463.29 -- Data Talk
FTSE 100 Index Ends the Week 1.26% Higher at 7051.48 -- Data Talk
Nike Down After Revenue Miss, Supply Chain Issues
Kansas City Fed Services Activity Index Slips But Stays Positive in September
VC Daily: Question: What to Make of Efforts in Congress to Lower Drug Prices?
Turkish Lira Falls Near Record Lows After Rate Cut; Norges Bank Raises Rates; Purchasing Managers Point to Slowing in U.S. and Europe
U.S. New Home Sales Rose in August
Rite Aid Expands Partnership With Uber
Salesforce.com on Track for Record High Close -- Data Talk
Nike Down Over 6%, on Pace For Largest Percent Decrease Since June 2020 -- Data Talk
read_this_n0w   Tuesday, 02/16/10 01:57:30 PM
Re: read_this_n0w post# 90665
Post # of 239695 
Preliminary files still available - since locally stored




ALS results IPLEX in small group of USA patients
Update by US patient group, relates to IPLEX made by Insmed - INSM (nasdaq)


We are pleased to present the Interim Report of the Investigational New Drug trial on the use of Iplex (mecasermin rinfabate) by middle-to-late stage Amyotrophic Lateral Sclerosis patients. This trial was conducted under the direction of Principal Investigator Michael E. Schafer, MD and Medical Director of ALS WORLDWIDE, with our assistance. We are hopeful the results will be informative and will serve to facilitate the future use of Iplex for others within the ALS community. While this is a small study, it has provided relevant results for the period from April 2009 through November 2009. For more detailed information, please review the information at the following links.

During the 30-week period of Iplex usage that comprised the first half (26 week study peeriod and follow-up four-week confirmation period) of the one year authorized investigational new drug trial, there was a remarkable parity between the apparent responsiveness of the individual patients compared to the aggregated group of patients at large. Symptoms monitored for their absence, presence, or their degree of severity included the following: Hyperreflexia; Tongue Movement; Swallow; Hand Strength; Shoulder Strength; Fatigue; Clonus; Nausea; Atrophy; Breathing; Lability; Lower Arm Strength; Fasciculations; Dizziness; Cramps/Pain; Weakness; Balance; Speech; Upper Arm Strength; Tremor/Palsy; Rigidity; Libido. In the consolidated 30 week period, individual symptoms showed a maximum decline of 9% (Balance) followed by 6% (Tremor/Palsy). The maximum improvement of an individual symptom was 39% (Fasciculations) followed by 28% (Fatigue). The critical function (Swallowing) improved by 25% and Breathing improved by 1%.

Compared to the normal relentless worsening in virtually all symptoms over any continuous 30-week period of time, the use of Iplex appears to have stabilized, if not improved, the condition of its users. Those using Iplex demonstrated an average improvement of symptoms of 9.3% (all symptoms combined) after the 30-week period.

There were no adverse events or serious adverse events during the 26-week study period. During the fourt week confirmation period, two serious adverse events occurred: one death from apparent unrelated to Iplex usage in week 28 and one death from apparent unrelated to Iplex usage in week 30.

In line with earlier Italian results


Dr. Schafer (lead investigator for USA patients) CV
From ALS Worldwide:

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences